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ABSTRACT 1 
    Inflammatory bowel diseases (IBD) can be broadly divided into Crohn’s disease (CD) and ulcerative colitis 2 
(UC) from their clinical phenotypes. Over 150 host susceptibility genes have been described, although most 3 
overlap between CD, UC and their subtypes, and they do not adequately account for the overall incidence 4 
or the highly variable severity of disease. Replicating key findings between two long-term IBD cohorts we 5 
have defined distinct networks of taxa associations within intestinal biopsies of CD and UC patients. 6 
Disturbances in an association network containing taxa of the Lachnospiraceae and Ruminococcaceae 7 
families, typically producing short chain fatty acids, characterize frequently relapsing disease and poor 8 
responses to treatment with anti-TNF-α therapeutic antibodies. Alterations of taxa within this network also 9 
characterize risk of later disease recurrence of patients in remission after the active inflamed segment of 10 
CD has been surgically removed. 11 
 12 
INTRODUCTION 13 
    There is strong evidence indicating that the intestinal microbiota is responsible for triggering 14 
inflammatory bowel disease (IBD): animal models of chronic intestinal inflammation are almost all 15 
mitigated when re-derived to germ-free status1,2; humans with IBD have altered reactivity to their intestinal 16 
microbes3; the genetic loci for human susceptibility to Crohn’s disease (CD) and/or ulcerative colitis (UC) 17 
mainly encode proteins required for innate or adaptive mucosal immune defense mechanisms and overlap 18 
with genes known to cause microbiota-sensitive intestinal inflammation in animal models4. Whilst no 19 
persistent pathogen has been consistently identified as being responsible for IBD, strategies reducing 20 
microbiota exposure such as surgical fecal stream diversion5, elemental diets or antibiotic treatment can 21 
have beneficial effects in particular IBD cases6-8.  22 
    The intestinal microbiota stabilizes during childhood, but with inter-individual variations9-11 and 23 
fluctuations according to diet12 or intestinal transit time13,14.  Microbial taxa compositions in IBD patients 24 
have been extensively studied (Extended Data Fig. 1a). These different studies have been carried out with 25 
different microbiological and sequencing techniques, on various ethnic populations, at different ages and 26 
stages in the trajectory of disease, using fecal or tissue specimens. Alterations in the relative proportions 27 
of taxa within the Bacteroidetes, Firmicutes and Proteobacteria in CD patients compared with UC or non-28 
IBD subjects are generally reported. Despite this, the overall picture remains very inconsistent (Extended 29 
Data Fig. 1 and 2). 30 
    Microbiota differences may account for i) a gap in the IBD prevalence that is inadequately explained by 31 
known CD/UC genetic susceptibilities15-17; ii) phenotypic differences in the severity and distribution of 32 
disease that are only partly explained from genetic and immunological studies15,18-20; and iii) a significant 33 
proportion of patients that are poorly responsive to current selective or non-selective immunomodulatory 34 
treatments21-23.  35 
     Within CD and UC there is immense variability in disease distribution, severity and responsiveness to 36 
treatment. These clinical disease behaviors are poorly predicted by host genetic susceptibility markers. 37 
Disease behavior, treatment responsiveness and environmental influences have not been comprehensively 38 
considered in studies of microbiota patterns in IBD so far (Extended Data Fig. 1b). Our hypothesis here was 39 
that microbiota composition and taxa networks underlie the phenotypic variability of established CD and 40 
UC that could be addressed with robust deep longitudinal information over many years for each patient. 41 
Given that important and potentially correctable differences should be reproducible in the same (central 42 
European) environment, we have determined microbiota changes according to disease phenotype that are 43 
robust to replication between two independent long-term longitudinal cohorts of patients.  We show here 44 
microbiota networks that are reproducibly related to long-term disease type and severity, the extent and 45 
position of the involved intestinal segments and responsiveness to different treatments.  46 
 47 
RESULTS 48 
Distinct microbial communities according to CD or UC diagnosis in IBD patients compared with controls 49 
    The microbial communities of IBD patients were assessed using 16S sequencing in biopsy samples 50 
obtained from a tissue biopsy biobank of the Swiss IBD cohort (Cohort 1). To validate the results a second 51 
independent cohort of patient biopsies (Cohort 2) including healthy, non-IBD controls was collected from 52 
Bern gastroenterology clinics (Supplementary Table 1).  53 
   Matching clinical deep metadata sets were assembled prospectively and retrospectively from patient 54 
records for both cohorts. In addition to gender, age, marital status, family history, specifics of diagnosis, its 55 
timing, and disease subtype at the outset, contemporaneously collected follow-up information for each 56 
patient included into trajectories of disease evolution with blood parameters, environmental exposures 57 
(alcohol and tobacco use), daily exercise, BMI, medication time-courses (antibiotics, corticosteroids, 58 
mesalamine, and immunosuppressants), nutritional supplements, disease complications, surgical 59 
resections and inter-current comorbidities.  60 
    As expected from known taxa predilection in the human large intestine24, the dominant bacterial 61 
phylotypes in the gastrointestinal (GI) tract of IBD patients from both cohorts and healthy controls were 62 
Bacteroidetes, Firmicutes and Proteobacteria, with a smaller proportions of Fusobacteria, Actinobacteria 63 
and Tenericutes (Supplementary Tables 1 and 2).  Average Firmicutes proportions are known to be higher 64 
in comparison with Bacteroidetes and we observed this in all GI segments of UC compared with CD in both 65 
cohorts but with very wide variability across subjects and sites (Extended Data Fig. 3a, b). As also expected 66 
from previous studies25, overall alpha diversity measured according to the Shannon and Simpson indices 67 
demonstrated significantly reduced diversity in CD samples compared with UC samples in both patient 68 
cohorts, and compared with healthy, non-IBD controls in Cohort 2 (Extended Data Fig. 3c,d).  69 
    The distinctiveness of the CD microbiota was confirmed by beta diversity analysis, demonstrating a 70 
clustering of samples according to IBD diagnosis for both cohorts with the same homogeneity by Bray-71 
Curtis dissimilarity metrics (p<0.001) (Fig. 1a,b) as well as UniFrac distance metrics (p<0.001) (Extended 72 
Data Fig. 3e-h).  73 
    We next evaluated specific microbial features associated with disease phenotypes that could be 74 
replicated at genus level in both independent cohorts (Fig. 1c). Comparison of relative abundances in CD 75 
and UC patients revealed multiple concordant significant differences at phylum (Actinobacteria, 76 
Firmicutes, Bacteroidetes and Proteobacteria) and genus level (Bifidobacterium, Coriobacteriaceae•, 77 
Barnesiellaceae•••, Clostridiales genus••, Prevotella (Prevotellaceae family), Prevotella•••, 78 
(Paraprevotellaceae family), Lachnospira, Faecalibacterium, Coprococcus, Roseburia, two Lachnospiraceae 79 
genera (• and ••), two Ruminococcaceae genera (• and ••), Ruminococcus, Enterobacteriaceae•, and 80 
Streptococcaceae•• (Fig. 1c and Extended Data Fig. 3i,j and Supplementary  Table 3). 81 
    From the identification of taxa that are selectively associated with CD, UC or controls that are robust to 82 
replication in two independent cohorts from central European environment, we compared these results 83 
compared with an unsupervised meta-analysis of previously published studies carried out in different 84 
contexts (Extended Data Fig. 1a). In general, different genera within Firmicutes are reported to be reduced 85 
in CD compared with controls, or IBD (where the study concerned grouped CD+UC) compared with controls 86 
(Group 1 in Extended Data Fig. 1a); further genera within Proteobacteria are increased in CD or CD+UC 87 
compared with controls (Group 2 in Extended Data Fig. 1a). For other taxa, our meta-analysis showed 88 
results that were largely inconsistent between different studies (Group 3 in Extended Data Fig. 1a) 89 
regardless of age, gender, ethnicity, sample type or sequencing method. We now show in Extended Data 90 
Fig. 1a (bold taxa labels) that our results verify the previous data for 8 of 11 taxa in Group 1 and 3 of 4 taxa 91 
in Group 2: Our results also show 18 significant additional taxa differences between CD and controls, or UC 92 
and controls that are robust to replication between the two cohorts in the heterogeneous Group 3. These 93 
changes that are seen between CD and UC are largely a consequence of differences between the CD 94 
microbiota and non-IBD controls, whereas UC microbial consortia are relatively similar to healthy subjects 95 
(Extended Data Fig. 4a,b).  96 
    Using our extended portfolio of emblematic taxa, machine learning enabled prediction of CD and UC 97 
clusters with 87.7% and 83.3% prediction accuracy for Cohort 1 and Cohort 2, respectively (Supplementary 98 
Table 4). Focusing on multiple predicted OTUs within specific genera, we confirmed that Ruminococcus 99 
gnavus was consistently increased in abundance in CD compared to UC, and Faecalibacterium prausnitzii 100 
was consistently reduced in both cohorts26,27 (Extended Data Fig. 4c,d). 101 
    We next used genome-scale metabolic models to analyze our sequencing data and elucidate how 102 
metabolism is modulated within microbial IBD communities28.  Principal component analysis (PCA) analysis 103 
illustrates robust data at the metabolic reaction level with consistent metabolic subsystems increased in 104 
CD belonging to B-vitamin and LPS biosynthesis, heparan sulfate and chondroitin sulfate degradation, and 105 
fatty acid oxidation (Extended Data Fig. 4e-j).  106 
    We also carried out a meta-analysis comparing IBD animal models including dogs, cats, and laboratory 107 
mice with the available human studies. In an unsupervised analysis, the microbiota clustered according to 108 
species (Extended Data Fig. 5a), and genetic models were the most representative of the changes seen in 109 
human IBD patients (Extended Data Fig. 5b,c). 110 
     In summary, the distinct CD and UC disease groups are characterized by altered bacterial composition 111 
and lower diversity in CD patients compared to UC patients and non-IBD subjects (Fig. 1a-c, Extended Data 112 
Fig. 3, 4a,b). Bacterial richness and diversity between UC and non-IBD were less pronounced (Extended 113 
Data Fig. 3c-f). Our results indicated that there is a greater net loss of potentially beneficial taxa in CD 114 
compared with UC (Fig. 1c, Extended Data Fig. 3i,j and 4a,b). These included Faecalibacterium capable of 115 
butyrate production; the secondary bile acid producer Oscillospira; the dietary carbohydrate utilizer 116 
Bifidobacterium; Ruminococcus which degrades mucus; and the complex carbohydrate utilizer Blautia29,30.  117 
 118 
Longitudinal comparisons of microbial community compositions between CD and UC patients 119 
    Most of the known IBD genetic risk factors that are shared between CD and UC are uninformative about 120 
disease subtypes20,31. Within distinctive clinical pathology and sites of GI tract involvement that define CD 121 
or UC32, disease subtypes may shape the severity and treatment responsiveness for individual patients. 122 
Whilst IBD is characterized by chronic relapsing-remitting intestinal inflammation, current published 123 
studies have characterized these diseases largely in generic terms that might be insensitive to the 124 
longitudinal disease course and/or treatment responsiveness (Extended Data Fig. 1b). Our study was 125 
therefore designed to combine deep longitudinal clinical phenotypes between CD and UC and the different 126 
disease subtypes, allowing us to replicate key findings using the two independent longitudinal cohorts.  127 
    In a subset of our patients, we had biopsies that were taken at different times in the clinical course of 128 
disease. In both cohorts, ordination analysis showed that microbiota profiles were personalized according 129 
to each individual, over periods ranging up to 9 years (Extended Data Fig. 6a). Individual taxa were generally 130 
stable over time (Extended Data Fig. 6b) even when there had been an inter-current change in disease 131 
activity defined according to clinical phenotyping (Extended Data Fig. 6c).  132 
    To address the question of variation in the microbiota compositions according to parameters of disease 133 
activity by alternative methods, we assessed the relationship of the microbiota composition to disease 134 
activity according to clinical indices of activity (CDAI for CD; MTWAI for UC) or fecal calprotectin 135 
measurements. Of 83 taxa analyzed, only Enterobacteriaceae• and Klebsiella in CD (Extended Data Fig. 6d), 136 
Ruminococcus••• and Prevotella in UC (Extended Data Fig. 6e) showed consistent compositional changes 137 
between the cohorts that were significantly aligned with clinical assessments of the disease activity (Fig. 138 
1d,e), and according to the calprotectin biomarker (Extended Data Fig. 6d,e).  139 
    From these findings that microbiota composition profiles were mainly personalized according to the 140 
patient rather than the current disease activity, we proceeded to consider whether microbiotas within 141 
individuals could be related to their overall disease course or treatment responsiveness. 142 
 143 
Co-occurrence pattern analysis of the intestinal ecosystems of IBD patients 144 
    We next used co-occurrence analysis to examine potential relationships between different taxa in either 145 
CD or UC patients. The complex microbial ecosystem of the human intestinal tract  is unevenly influenced 146 
by individual taxa within different microbial consortia10,11,24: the ecological roles of individual community 147 
members are fundamentally important for overall biodiversity and key to human health33,34. 148 
Computationally derived co-occurrence associations are useful to infer influences between taxa in a range 149 
of ecosystems and are a starting point to examine the mechanisms of community construction and 150 
maintenance35,36.  151 
    We first tested whether co-occurrence associations would differ strongly across different segments of 152 
the GI tract. All patients in both cohorts of our study had received prior intestinal purging to remove faecal 153 
material and allow safe endoscopy with biopsies. Since purging involves substantial fluid flow along the 154 
length of the small and large intestine, as expected we did not see major microbial profile differences 155 
between different intestinal segments of individual patients (Extended Data Fig. 7a-f, Supplementary Table 156 
5). Likely also because of the mixing effect of purging, we also found that the mucosal microbiota diversity 157 
of inflamed and non-inflamed segments within the same patient were indistinguishable, independently of 158 
disease type (Extended Data Fig.7g-j, Supplementary Table 5).   159 
    We then used all sequenced biopsies from different locations of the IBD patients’ gut as replicate 160 
sampling groups for CD and UC independent ecosystems to address whether co-occurrence patterns 161 
among the microbial communities are the same in the different pathological contexts. We identified 2 162 
consistent modules of co-occurring gut microbes for CD (CDA and CDB) and for UC (UCA and UCB) (Fig. 2 and 163 
Extended Data Fig. 8).  164 
    We found similar complexity and composition of the networks for both disease groups in each of the 165 
two cohorts [Supplementary Table 6 and 7]: The highest ‘betweenness centrality scores’ conceivably 166 
identifying keystone species within each ecosystem, showed that Firmicutes was a potential keystone 167 
phylum determining the network in both CD and UC disease groups of both cohorts (Extended Data Fig. 168 
8a,b). However, Tenericutes for CD in Cohort 1 and Fusobacteria for UC in both cohorts were also likely 169 
important keystone phyla (Extended Data Fig. 8a,b). Measures of eigenvector and betweenness centrality 170 
showed in both cohorts that nodes contribute equivalently to the networks although there were more 171 
complex relationships of microbial taxa in CD (Extended Data Fig. 8c,d). 172 
    Based on betweenness centrality of each vertex, the top genera identified as keystone taxa in both 173 
cohorts with higher scores in CD compared to UC were Streptococcus, Ruminococcus, Bifidobacterium, 174 
Propionibacterium, Corynebacterium, Coprococcus, and Blautia (Extended Data Fig. 8e,f). Further, the 175 
degree centrality measure helps identify the most prominent and influential taxa that we might miss with 176 
betweenness and Eigenvector centrality measures. Interestingly, Faecalibacterium, Ruminococcus••• of 177 
the Lachnospiraceae family, Fusobacterium, Haemophilus, and Parabacteroides have some of the lowest 178 
betweenness scores although they show amongst the highest out-degree scores (number of edges 179 
originating in a node) in both disease groups of both cohorts, implying that Faecalibacterium and 180 
Ruminococcus••• are some of the most influential taxa in Cohort 1 (Extended Data Fig. 8g,h) and Cohort 2 181 
(Extended Data Fig. 8i,j) independently of disease status. Overall, whilst there is similar complexity of the 182 
networks for both disease groups with relatively consistent modules of co-occurring microbial taxa within 183 
each ecosystem, the module labelled Cluster CDA in both cohorts connects nodes of Lachnospira, Blautia, 184 
Dorea, Coprococcus, Ruminococcus, Ruminococcus•••, Faecalibacterium, Roseburia, Oscillospira and 185 
Bilophila (Fig. 2): a similar Cluster UCB is present in patients with UC, although it is less connected, and 186 
overlaps with a Cluster ContB that is found in non-IBD controls (Fig. 2). As shown subsequently in the paper, 187 
reductions in members of Cluster CDA within the microbiota of CD patients generally characterize a worse 188 
outcome, less healthy lifestyles, poor responses to treatment and are associated with an increased risk of 189 
subsequent relapse in patients where the active segment of CD has been surgically removed. 190 
 191 
Identification of critical variables in shaping the intestinal microbiota of IBD patients 192 
    Analyses of variability of the microbiota with chronic disease phenotype parameters suffer from the 193 
limitations that i) correlations seen may be direct or indirect and ii) that the strength of these correlations 194 
may be disproportionate if taken in isolation from parameters of subject ageing, weight or other 195 
environmental influences. To allow a reasonable perspective of the relative influences of disease 196 
parameters or other personal variables, we then used the algorithms in the Hierarchical All-against-All 197 
Association (HAllA) tool for multi-resolution associations in high-dimensional, heterogeneous datasets with 198 
high power 37. Analysis performed at phylum (Fig. 3a,c) and genus rank (Fig. 3b,d) identified BMI, age at 199 
sampling/diagnosis as the most important variables correlating with gut microbiota of IBD patients. To a 200 
lesser extent, disease type, location and behavior, and prior surgery were also important variables showing 201 
interactions with more than 60-70% of most abundant taxa of IBD patients. Overall life styles (including 202 
sport, smoking and alcohol consumption) were correlated with the gut microbiota profile in Cohort 1 (Fig. 203 
3a-d): of these, smoking was the most significant factor. In contrast, biopsy location and inflammation 204 
status at the time of sampling were correlated with only a few taxa, which were largely inconsistent 205 
between cohorts.  206 
    Correlations with patient age and BMI in HAllA are consistent with published data showing strong effects 207 
of nutrition and intestinal physiological parameters on the microbiota12-14. Although both CD and UC show 208 
age-dependent incidence, and active disease may cause weight loss, the greater strength of microbiota 209 
association with age at diagnosis than disease type or BMI compared with disease activity argues that these 210 
are likely not dependent variables. Taken together with the similarities in taxa co-occurrence analysis at 211 
phylum and genus level between patients with CD or UC (Fig. 2), the relatively weaker correlations of the 212 
microbiota with disease parameters and responsiveness to treatment (Fig. 3) indicate that detailed minor 213 
compositional changes may be associated with disease type or subtype on a background of larger effects 214 
of body habitus or age.  215 
 216 
The assessment of critical variables that may be related to the microbial profile including disease status, 217 
therapeutics and environmental factors 218 
    We next focused specifically on the relationship of the microbiota within the grouping of either CD or UC 219 
patients, according to the detailed disease phenotype or subtype, known trigger factors and treatment 220 
responsiveness using a sparse multivariate statistical approach.  221 
    We first analysed whether the patient’s lifestyle such as alcohol consumption, smoking habit, or physical 222 
activity were associated with alterations of the gut microbiota composition (Supplementary Table 8). We 223 
only identified significant changes in microbial taxonomy (in every case corrected for multiple testing) in 224 
relation to host lifestyle in CD patients. Increasing exercise was positively correlated with the relative 225 
abundance of taxa from the Firmicutes and Bacteroidetes phyla, including Clostridales•, Blautia, 226 
Barnesiellaceae•, Faecalibacterium, Eryselotrichaceae•, Ruminococcaceae• genera and negatively 227 
correlated with Veillonella abundance (Extended Data Fig. 9a). Tobacco smoking or alcohol consumption 228 
Parabacteroides and Clostridales•• were respectively associated with in CD: both were negatively 229 
associated with Sutterella (Extended Data Fig. 9b,c). Parabacteroides was reduced in familial CD patients 230 
(Extended Data Fig. 9d). Notably both exercise in CD patients which is indicative of a healthier life-style 23 231 
is associated with taxa including Clostridiales••, Blautia, Faecalibacterium, Eryselotrichaceae•, 232 
Ruminococcaceae• that are represented in Cluster CDA of the co-occurrence analysis (Fig. 2), although we 233 
cannot distinguish whether the alterations are either bias due to reduced disease activity in those able to 234 
participate in sport38 or a beneficial alteration in microbiota composition. 235 
    Disease therapy including monoclonal antibody treatment against TNF-α and steroid use are effective 236 
treatments for many IBD patients39-41. Unfortunately, not all patients are responsive to these therapies 237 
likely because of the variable redundancy of different triggering mechanisms of intestinal inflammation 238 
and the variable redundancy of TNF-α as an inflammatory cytokine42. We asked whether the 239 
responsiveness of IBD patients to different therapies could be correlated with differences in microbiota 240 
composition. Initial microbial analysis of CD and UC samples showed that there was no significant 241 
difference in alpha diversity for either cohort based on whether the patient had responded to treatment 242 
(Extended Data Fig. 9e,f). However, we did find significant differences in gut microbial composition 243 
between patients responding or not responding to TNF-α inhibitor therapy (Fig. 4a-c). Although there were 244 
no significant differences in the small numbers of UC patients that had been treated in both cohorts, 245 
comparison of the CD groups responding to treatment versus the CD patients failing to respond to 246 
treatment, showed and replicated increased Bifidobacterium, Collinsella, Lachnospira, Lachnospiraceae•, 247 
Roseburia, Eggerthella taxa and reduced Phascolarctobacterium associated with treatment success (Fig. 248 
4b,c). Bifidobacterium are well recognised for their capacity for metabolism of oligosaccharides that may 249 
be resistant to host digestion and have been used as probiotics in IBD43. Lachnospiraceae• and Roseburia 250 
are both members of association CDA (Fig. 2) and are characterized by production of short chain fatty acids 251 
that are a carbon source for intestinal epithelial cells and inducers of regulatory T cells44,45. 252 
Phascolarctobacterium is common in the human GI tract46, and can produce acetate and propionate, 253 
although it has also been associated with inflammatory dysbiosis in animal models47. 254 
    We asked whether the responsiveness of IBD patients to corticosteroid therapies could also be 255 
correlated with differences in microbiota composition. However, although significant differences in gut 256 
microbial taxa composition between groups responding to treatment versus groups failing to respond were 257 
observed in the PCoA analysis of both cohorts (Extended Data Fig. 9i,j), unlike the results with anti-TNF-α 258 
biological treatments, these were not replicated between the different cohorts (Fig. 4d, Extended Data 259 
Fig.9k-m).  260 
    A major burden for patients with CD and UC is that the diseases follow a relapsing-remitting course of 261 
recurrent exacerbations and symptomatic improvements over many years, with unpredictable effects on 262 
morbidity, quality of life and the need for healthcare (Supplementary Table 9). The analysis of samples 263 
from patients with a quiescent or a relapsing course  showed that whilst there were no significant 264 
differences in microbial alpha diversities either cohort, in CD, Eggerthella, Clostridiales••, and Oscillospira 265 
showed consistent replicated increases in relative abundance in patients with quiescent disease over time 266 
while Enterobacteriaceae•, Enterobacteriaceae•• and Klebsiella were associated with a more severe 267 
clinical course  (Fig. 1d,e, Extended Data Fig. 9n-r). Oscillospira associated with the more benign course of 268 
CD are also members of association Cluster CDA in Cohort 1 and in Cluster CDC together with Eggerthella in 269 
Cohort 2  (Fig. 2). 270 
 271 
Disease location is secondary determinant in gut microbiota profile of IBD patients  272 
    Separating the CD patients according to whether they had colonic disease, or ileal CD disease (comprising 273 
ileal CD and ileo-colonic CD subtypes combined), we found no significant differences between non-IBD, 274 
colonic UC, and colonic CD samples, although the gut microbiota composition of patients with colonic CD 275 
was closer to the microbiota of patients with UC than to that of patients with ileal CD, as previously 276 
reported 32 (Fig. 5a-c).  Metabolic reaction set analysis of IBD subtype microbiotas, that were consistently 277 
seen across the two patient cohorts, revealed that LPS biosynthesis, vitamin B2 and vitamin B7 metabolism 278 
were higher in colonic CD subtype compared with (colonic) UC (Fig. 5d), and LPS biosynthesis, peptide and 279 
folate metabolism, fatty acid synthesis, chondroitin sulphate and heparan sulphate degradation were 280 
functionally elevated in patients with ileal CD subtype compared with UC (Fig. 5e). Glycerophospolipid 281 
metabolism and cell wall biosynthesis were increased in UC microbiota compared with colonic CD or ileal 282 
CD respectively. There was no significant metabolic reaction set differences between ileal and colonic CD, 283 
although any distinction may be confounded by colonic purgatives prior to sampling as discussed 284 
previously. 285 
 286 
 Post-surgical CD patients have altered intestinal microbiota prior to disease recurrence  287 
    Although the outlook for IBD patients has been transformed by the advent of treatments that can be 288 
directed against selected pro-inflammatory pathways, surgery is still required in up to 40% of CD and 30% 289 
of UC patients at some point during their lifetime48,49. UC surgery normally comprises removal of the entire 290 
colon and hence the source of the intestinal inflammation. Before the advent of current biological 291 
therapies, clinical studies established that removal of inflamed intestinal segments in CD cannot cure the 292 
disease, because without ongoing treatment CD recurs in over 70% of patients at the anastomotic margin 293 
where previously uninflamed segments have been joined 50. Post-surgical patients represent and extremely 294 
interesting group because they usually do not have detectable Crohn’s disease (since it has been surgically 295 
removed), but they will almost inevitably acquire it again unless they receive immunosuppressive 296 
medications. Thus, the microbiota in patients after surgery may be emblematic of the patient susceptible 297 
to CD (potential CD), without it being present at the time of sampling. 298 
    We therefore compared the post-operative microbiota in CD patients that had already undergone 299 
resection of the ileo-cecal region or a segment or small intestine, with CD patients that had not needed an 300 
operation. The operated CD patients had distinct gut microbial profiles with reduced species richness in CD 301 
samples from both cohorts collected >3 months post-operatively (Fig. 6a,b). Further, composition 302 
differences of the intestinal microbiota were found between inactive CD patients with or without prior 303 
surgery (Fig. 6c, d). The taxa that were principally included replicated reductions in the following members 304 
of Cluster CDA, Ruminococcaceae•, Oscillospira, Ruminococcus and Bilophila. In both cohorts 305 
Parabacteroides and Clostridiales• were also reduced in inactive post-surgical patients, and 306 
Enterobacteriaceae•• were significantly and reproducibly increased (Fig. 6e,f). These compositional 307 
changes in post-surgical CD patients without active disease, but with an almost inevitable probability of 308 
relapse in a previously uninvolved intestinal segment if untreated (biased towards reductions in Cluster 309 
CDA) may be capable of triggering CD relapse.  310 
    The implication that a disrupted composition of Cluster CDA makes patients susceptible to CD relapse, 311 
even in post-surgical CD patients who temporarily have no activity because the active segment has been 312 
removed, implies that this cluster may be a biomarker of resistance to relapse of active disease 313 
independently of current inflammatory activity. It would follow that Cluster CDA taxa are not themselves 314 
intrinsically associated with CD disease activity, unlike the Enterobacteriaceae• (Extended Data Fig. 6d). 315 
We found no significant changes in the Cluster CDA taxa in longitudinally studied patients judged by 316 
alterations in disease severity status over time (Extended Data Fig. 10a).  As an alternative approach, we 317 
also asked whether the calprotectin level could be a more sensitive luminal inflammatory biomarker for 318 
possible alterations in the association cluster CDA with increased intestinal inflammation. Again, no CDA 319 
taxon showed a significant correlation with calprotectin levels (Extended Data Fig. 10b). Overall, this data 320 
supports the idea of importance to this cluster of taxa to inhibit relapse, rather than being associated as a 321 
biomarker for the patients with the most inflammatory and immunologically active disease. 322 
 323 
DISCUSSION 324 
    In this paper, we report the relationship of intestinal biopsy microbiotas from patients with UC and CD 325 
taken from two cohorts of patients over many years and capturing information about clinical phenotypes 326 
including responsiveness to different treatments, life-style differences and the severity of the relapsing-327 
remitting clinical course. In our patient cohorts relatively few taxa were shown to be correlated with the 328 
current activity of disease, whether assessed by clinical phenotyping or by the fecal calprotectin 329 
inflammatory biomarker.  330 
    We have confirmed previous reports of the microbiota differences between CD patients and controls, 331 
and UC patients and controls. In addition to the known associations of Faecalibacterium and the Firmicutes 332 
phylum with UC, and Bacteroidetes and Ruminococcus••• with CD, we have now shown (and replicated 333 
between cohorts) that other Firmicutes genera (including Lachnospiraceae•, Clostridia••, Roseburia, 334 
Blautia, Ruminococcus genus of the Ruminococcaceae family) are reduced in CD compared with UC, whilst 335 
a Ruminococcus••• genus of the Lachnospiraceae family was increased in CD compared with UC. 336 
   That the dysbiosis we observed may be causal is supported by the special situation in patients where CD 337 
segments have been surgically removed, yet relapse in another previously uninvolved part of the intestine 338 
is extremely likely without immunosuppression.  339 
    In line with other studies that show major effects from nutrition and host intestinal physiology on the 340 
microbiota13,14, we have found that the differences that are attributable to CD or UC, or to the different 341 
lifestyle or therapeutic factors are far less than those engendered by age or body habitus. Since IBD are 342 
highly heterogeneous diseases, we need to be cautious about associations between microbial gut profiles 343 
and clinical phenotypes with small but significant effect sizes. Nevertheless, a major biomedical problem is 344 
to understand why the phenotypic behavior and therapeutic responsiveness of CD and UC and its subtypes 345 
is so different between patients. Here we could show and replicate between cohorts that increased 346 
Bifidobacterium, Collinsella, Lachnospira, Lachnospiraceae•, Roseburia, Eggerthella taxa were related to 347 
the successful outcome of anti-TNF-α treatment in CD. This is consistent with the finding that 348 
Lachnospiraceae• and Roseburia taxa are reduced in CD, and that these taxa produce short chain fatty 349 
acids as a carbon source for intestinal epithelial cells and induction of regulatory T cells44,45. We found that 350 
Roseburia was a likely keystone taxon in microbial consortial association analysis of CD but not UC. In 351 
murine and in vitro models Roseburia can promote innate gut immunity of antimicrobial peptide up-352 
regulation and improved gut barrier function in addition to regulatory T cell induction51. Interestingly, 353 
reduction of two Lachnospiraceae, Blautia and Roseburia also predict pouchitis in patients that have 354 
undergone colectomy with reconstruction of a pouch of small intestine to substitute the rectum52. Whilst 355 
reduced Roseburia has also been reported compared with controls in UC53, our findings are that the effect 356 
of the taxon on the clinical course is strongest in CD. We also found that Clostridiales•, Blautia, 357 
Faecalibacterium, Eryselotrichaceae•, Ruminococcaceae• were associated with taking regular exercise in 358 
CD. Blautia, Faecalibacterium and Ruminococcus are all likely keystone taxa in CD and UC, but with greater 359 
connectivity in the association analysis in CD. Many of the above taxa are connected in Cluster CDA in the 360 
association analysis (Fig. 2).  361 
    Many of the taxa that are altered in association with a poor prognosis of disease course, therapeutic 362 
unresponsiveness, a less healthy lifestyle or likelihood of relapse in postsurgical patients are within the 363 
Cluster CDA, identified through taxa association analysis. This contains taxa characterized by short chain 364 
fatty acid production through different metabolic pathways54 which may increase the availability of 365 
intraluminal intestinal oxygen and allow facultative aerobes such as Enterobacteriaceae family to bloom 366 
through alterations in intestinal epithelial cell metabolism55. We found no significant correlations between 367 
intestinal inflammation and relative abundance of CDA taxa measured either according to clinical 368 
assessment of alterations in disease activity or in relation to the fecal calprotectin inflammatory biomarker. 369 
Taken together, this supports the idea of importance to this cluster of taxa to inhibit the disease, likely in 370 
a particular context of individual patient genetic susceptibility, rather than merely being associated as a 371 
biomarker for the patients with the most inflammatory and immunologically active disease. 372 
    Our data have shown a cluster of taxa including those characterized by their short chain fatty acid 373 
production that generally distinguish CD from UC, and are predictive of a quiescent course, a healthier 374 
lifestyle and responsiveness to anti-TNF-α therapy. These taxa have been replicated across two patient 375 
cohorts in the study and are deficient in patients after surgical resection that can be considered at very 376 
high risk for CD relapse despite removal of the earlier diseased intestinal segments. There is considerable 377 
interest in manipulation of the microbiota as an adjunctive therapy to improve the course and 378 
responsiveness of disease. Our results predict that fecal transplants or directed manipulation of the 379 
intestinal microbiota may be most successful where defects in Cluster CDA can be corrected. 380 
 381 
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 545 
 546 
MAIN FIGURE LEGENDS 547 
 548 
Figure 1. Distinct microbial features associated with IBD patients. (a,b) Microbial clustering is shown 549 
based on Bray-Curtis dissimilarity principal coordinate analysis (PCoA) metrics using 2-4 intestinal biopsy 550 
samples per patient. 346 patients with IBD in Cohort 1 (a) and 156 patients with IBD and 227 non-IBD 551 
subjects in Cohort 2 (b) were included into the study. Non-parametric analysis of variance (Adonis) was 552 
used to test significant difference between groups on PCoA plot; in each case p<0.01 for each disease group 553 
in each cohort and non-parametric two-sided Mann-Whitney U-test was used to analyze significant 554 
differences between ranks ± s.d for PC1 and PC2. p<0.05 was considered significant. Ellipsoids represent a 555 
95% confidence interval surrounding each disease group. Box-and-whisker plots display 1st and 3rd quartiles 556 
and whiskers go from each quartile to the minimum or maximum. Significant comparisons are shown on 557 
the figure (b). Groups are not significantly different among each other on PC2 axis (b). (c) Overall 558 
representation of overlapping significant taxa of disease groups between Cohort 1 and Cohort 2. (d, e) Taxa 559 
significantly associated with “active” or “quiescent” clinical course in each cohort are plotted as relative 560 
abundance ratios in CD (d) and UC (e) disease groups. 494 CD and 447 UC samples in Cohort 1 (d) and 226 561 
CD and 195 UC in Cohort 2 (e) were analyzed. Statistical analysis for taxonomy results were performed 562 
using MaAsLin pipeline with BH-FDR (q value) (c-e). q<0.05 was considered significant and p value showing 563 
the trend (p<0.05 and q<0.2) and are indicated in the figures (d,e). Taxa with open bars show opposite 564 
relative abundance ratio between cohorts. • denotes classified but unnamed genus, ••denotes unclassified 565 
genus, and ••• denotes taxa are recommended under different family based on genome trees in 566 
Greengenes database.  567 
 568 
Figure 2. Microbial co-occurrence analysis of IBD and non-IBD subjects with GI ecosystems. (a,b) 569 
Ecosystem-specific co-occurrence patterns at genus level are visualized using network diagrams where 570 
microbial taxa represent nodes; the presence of a positive co-occurrence relationship based on correlation 571 
is represented by an edge for Cohort 1 (a) and Cohort 2 (b). Co-occurrence relationships with strong 572 
Spearman’s correlation coefficient (r-value > 0.5 and p<0.05) are depicted with network diagram for each 573 
disease. Each cluster was assigned with a subscript to related disease or non-IBD control (e.g. CDA, UCA, 574 
ContA). 575 
 576 
Figure 3. Clinical determinants correlate with intestinal microbiota composition of IBD patients. (a-d) 577 
Hierarchical analysis performed using end-to-end statistical method (HAllA) at phylum (a, c) and genus rank 578 
(b, d) for Cohort 1 (a,b) and Cohort 2 (c,d). Significant metadata among many clinical parameters was 579 
plotted after BH-FDR correction. q<0.05 was considered significant (a-d). Association rank was sorted by 580 
high similarity score. The color intensity of the heat-map (pairwise normalized mutual information [NMI]) 581 
and numbers in cells identify significant pairs of features (clinical determinants vs. microbial composition) 582 
of IBD patients. 583 
 584 
Figure 4. Intestinal microbiota composition of IBD patients with responsiveness to anti-TNF-a or 585 
corticosteroid therapies. (a) Microbial clustering is shown based on Bray-Curtis dissimilarity PCoA metrics 586 
of intestinal biopsy samples from IBD patients responding or non-responding to anti-TNF-a therapy 587 
showing reproducibility in both cohorts. CD (solid line) and UC (dashed line) are used to identify the disease 588 
groups in PCoA plot. Ellipsoids represent a 95% confidence interval surrounding each group. Adonis test 589 
assessed the significant difference between groups in PCoA plot: p < 0.01 is for each compared group in 590 
both cohorts. (b) Overall representation of overlapping significant taxa of responding and non-responding 591 
groups in each cohort are shown using phylogenetic trees for anti-TNF-a therapy. Closed circles correspond 592 
to Cohort 1 and open circles correspond to Cohort 2, green coloration represents higher relative 593 
abundances in responding groups and red coloration represents higher relative abundance in non-594 
responding groups. Significant taxa are plotted with respective circles. (c) Significant unique microbial taxa 595 
identified as a signature of responding (success) and non-responding (failure) groups CD and UC are shown 596 
for Cohort 1 and Cohort 2 after using MaAsLin with BH-FDR (q value). (d) Overall representation of 597 
overlapping significant taxa of responding and non-responding groups in each cohort are shown using 598 
phylogenetic trees for corticosteroid therapy. q<0.05 was considered significant and are plotted (b-d). 88 599 
success and 91 failure CD samples with 19 success and 48 failure UC samples in Cohort 1 and 129 success 600 
and 27 failure CD samples with 53 success and 18 failure UC samples in Cohort 2 were analyzed (a-d). 601 
 602 
Figure 5. Disease locations are critically important determinants that correlate with intestinal microbiota 603 
of IBD patients.  (a,b) Microbial composition differences in IBD patients within different disease locations 604 
in Cohort 1 (a) and Cohort 2 (b) are plotted using beta diversity (Bray-Curtis dissimilarity PCoA) and alpha 605 
diversity (Shannon and Simpson index). Ellipsoids in PCoA plots represent a 95% confidence interval 606 
surrounding each group and Box-and-whisker plots display 1st and 3rd quartiles and whiskers go from each 607 
quartile to the minimum or maximum. There is significant separation between groups on PCoA plot 608 
(p<0.05). Significant differences between groups in alpha diversity analysis were determined by an ordinary 609 
one-way ANOVA corrected for multiple comparisons using BH-FDR. (c) Only significant bacterial abundance 610 
differences between colonic CD, ileal CD and colonic UC samples are plotted using the samples identified 611 
in (a,b). Differences between tested groups were determined using MaAsLin with BH-FDR correction (q 612 
value). Asterisk indicates the similar significant taxonomic changes observed in Cohort 2. (d,e) Only 613 
significantly different metabolic subsystems in colonic CD samples (d) and ileal involved CD samples (e) 614 
when compared with UC samples are shown. q<0.05 was considered significant (c-e) and error bars on box 615 
plots are standard deviations (d,e). The same samples described in (a,b) were used for analysis of metabolic 616 
subsystems (d,e). 370 ileal, 110 colonic and 447 UC in Cohort 1 and 203 ileal, 28 colonic and 221 UC in 617 
Cohort 2 were used for analysis (a-e). 618 
 619 
Figure 6. Altered microbiota profiles in inactive CD patients following surgical resection of active disease 620 
segments. (a-d) Species richness between CD patients following surgery or without surgical resection was 621 
calculated using alpha diversity (Shannon and Simpson indices) for Cohort 1 (a) and Cohort 2 (b). Box-and-622 
whisker plots display 1st and 3rd quartiles and whiskers go from each quartile to the minimum or maximum. 623 
Microbial composition differences between these samples was calculated with PCoA on Bray-Curtis 624 
distance for Cohort 1 (c) and Cohort 2 (d). Blue color corresponds to CD patients having undergone surgical 625 
resection and red color corresponds to CD patients without surgery. Ellipsoids represent a 95% confidence 626 
interval surrounding each group (c,d). Non-parametric two-sided Mann-Whitney U-test and Adonis test 627 
were used to identify the statistical significant differences between groups for alpha (a,b) and beta diversity 628 
(c,d), respectively. There is a significant separation on PCoA plots between compared groups analyzed in 629 
(c) and (d) (p<0.05) (e, f) Only significant taxa (q<0.05) associated with surgical resection status are plotted 630 
as relative abundance ratio for CD in Cohort 1 (e) and Cohort 2 (f). In Cohort 2, non-significant data (q>0.05) 631 
was shown with “ns” (f). 105 (+) and 109 (-) samples in Cohort 1 (a) and 96 (+) and 371 samples (-) in Cohort 632 
2 were analyzed (a-f). 633 
 634 
 635 
 636 
 637 
     638 
METHODS 639 
Cohorts and study design  640 
Biopsy samples in this study were collected either a) in the Swiss IBD cohort study124 which has included 641 
more than 3500 patients (Cohort 1; approximately 5000 intestinal biopsies have been submitted to the 642 
Biobank Cohort) or b) newly recruited IBD patients and non-IBD subjects in the framework of the human 643 
intestinal community project of Bern University Hospital (Cohort 2). Cohort 1 includes biopsy samples from 644 
teaching hospitals, community hospitals and office practices in Switzerland. For all patients included in the 645 
cohort, deep longitudinal clinical and investigational phenotyping for an average of 5.7 years (range 1-11 646 
years) was sequentially taken over at least annual follow-ups. Unlike the Swiss IBD cohort, which had 647 
focused exclusively on inflammatory bowel disease, Cohort 2 included asymptomatic control patients 648 
undergoing screening colonoscopies without macroscopic or microscopic abnormalities, in whom all 649 
measured hematologic and clinical chemistry parameters were normal. Non-IBD biopsy samples were 650 
collected from subjects that were registered for a screening ileo-colonoscopy without any gastrointestinal 651 
symptoms, no suspected functional intestinal symptoms and where all other biochemical and 652 
hematological work-up was negative.  653 
    Inclusion criteria for Swiss IBD cohort patients were on established Lennard-Jones criteria125, confirmed 654 
by radiological, endoscopic and histological findings. Subject to informed consent for the longitudinal 655 
study, non-residents of Switzerland and patients unable or unwilling to provide blood samples were 656 
excluded. At inclusion, the patient’s physician filled an enrolment questionnaire to make a clinical 657 
evaluation of the disease activity (CDAI, HBI for CD and MTWAI, SCCAI for UC), the disease extent and 658 
location based on the Montréal classification, including extraintestinal manifestations, previous surgery 659 
(bowel resection or perianal), complications (fistula, stenosis, anaemia, osteoporosis), family history, 660 
duration of disease, smoking status, previous treatment success/failure and current therapy and dosage, 661 
as well as laboratory data (C-reactive protein, hemoglobin, auto-antibodies, from 1244 patients also stool 662 
calprotectin). Clinical treatment for IBD was scored (5-ASA preparations, steroids, thiopurines, 663 
methotrexate, tumor necrosis factor α (TNF-α) inhibitors or other biologicals) as well as the use of other 664 
concurrent medications and non-IBD surgeries. The clinical follow-up was on an annual basis and 665 
prospectively collected by the clinician or a study nurse with an additional questionnaire about their 666 
psychosocial situation (quality of life, depression and anxiety) and clinical IBD trajectory (disease activity, 667 
hospitalization, change in medication, adherence, surgeries). Hard copy data from the enrolment and 668 
clinical follow-up were then digitalized using Access 2010 (Microsoft, USA).  669 
    The inclusion criteria and data collection for consenting patients for the local Bern cohort were similar, 670 
except that patients were diagnosed and followed up in the Bern University Hospital (Inselspital) IBD clinic 671 
and in the Bern City Hospitals.  672 
 673 
Clinical data extraction, categorization and analysis 674 
    Structured clinical metadata was prospectively collected according to pre-determined standards 675 
containing variables of Cohort 1 and Cohort 2 (documented electronically using Research Electronic Data 676 
Capture (REDCap) database126). These metadata were imported and processed as dataframe in R 677 
(http://www.r-project.org) using xlsx package. Assessment of the microbiota composition from intestinal 678 
biopsies was then analyzed according to parameters including the type, course and severity of disease 679 
using the detailed clinical criteria summarized in Supplementary Table 1 for Cohort 1 and Supplementary 680 
Table 2 for Cohort 2. Statistical analyses were performed using Student’s t-test, Wilcoxon’s rank sum test 681 
and Pearson’s chi-squared test to test normality between groups. 682 
 683 
Ethics statement 684 
Licensed gastroenterologists collected biopsy samples and clinical data of patients identified as CD or UC 685 
and non-IBD subjects. The SIBDC study (Cohort 1) protocol was approved by the Ethics Committee of the 686 
Kanton Zurich (reference KEK-ZH-number 2013-0284) and this cohort is also registered with Trials 687 
Registration Number NCT02849821. The Bern Human Intestinal Community project (Cohort 2) was 688 
approved by the Bern Cantonal Ethics Commission (Ref: KEK-BE: 251/14 and 336/14) with signed informed 689 
consent was obtained from all participants. Bern cohort data were anonymized and collected in EDC 690 
(electronic data capture) system (REDCap)126, activated for the trial after successfully passing formal quality 691 
controls. The Bern EDC system and the database are hosted by the Clinical Trial Unit of Bern University. 692 
The study complies with all relevant ethical regulations. 693 
 694 
DNA extraction from human biopsies  695 
    Intestinal endoscopic biopsies were initially collected into 2ml microfuge tubes containing 500-600 µl 696 
RNAlater (Sigma-Aldrich) and stored at -20°C prior to DNA extraction protocol127. Total DNA was isolated 697 
using AllPrep DNA/RNA Mini Kit (Qiagen) according to the manufacturer’s instructions.  Briefly, 600 µl of 698 
Buffer RLT Plus 2-mercaptoethanol and a metal bead were added into each tube. Samples were then 699 
homogenized with the Retsch Tissue Lyser (QIAGEN) at 30Hz for 3 min, followed by 3 min centrifugation at 700 
13 000g (Eppendorf). Supernatants were transferred into the AllPrep DNA mini spin column and 701 
centrifuged at 9 000g for 30 sec. DNA attached to spin columns was washed/de-salted using 500 μl of 702 
Buffer AW1 and Buffer AW2. Lastly, DNA samples were eluted with 25-30 μl EB buffer into 1.5 ml microfuge 703 
tubes. The concentration and purity of the isolated DNA samples were analyzed in NanoDrop® (Thermo 704 
Scientific). 705 
 706 
Microbial profiling of biopsies 707 
    1255 samples from Cohort 1 and 1846 biopsy samples from Cohort 2 were used in this study.  The V5/V6 708 
region of 16S rRNA genes was amplified with InvitrogenTM PlatinumTM Taq DNA polymerase from 1000-709 
2000 ng of DNA using a range of oligonucleotide primers specific for the domains V5 and V6 of rDNA 710 
bacteria. Specifically, all forward core primers had been modified by the addition of a PGM sequencing 711 
adaptor, a ‘GT’ spacer and unique barcode that allowed us to have up to different 96 barcodes. The 712 
expected product length was ~350 bp including adaptors and barcodes. Bacteria-specific primers (forward 713 
5’-CCATCTCATCCCTGCGTGTCTCCGACTCAGC-barcode-ATTAGATACCCYGGTAGTCC-3’ and reverse 714 
5’-CCTCTCTATGGGCAGTCGGTGATACGAGCTGACGACARCCATG-3’) were used128,129. PCR conditions 715 
consisted of an initial 5 min at 94°C denaturation step, followed by 35 cycles of 1 min denaturation at 94°C, 716 
20s annealing cycle at 46°C and 30s extension cycle at 72°C, with a final extension for 7 min at 72°C. 717 
Samples were kept at 4°C until loading into an 1% agarose gel. Amplicons were purified using Gel Extraction 718 
Kit (Qiagen) after gel electrophoresis for 1 hour. The concentrations of amplicons were then evaluated by 719 
Qubit 3.0 Fluorometer (ThermoFisher) prior to library preparation and used at 26pM. To prepare template-720 
positive Ion PGMTM Template OT2 400 Ion SphereTM Particles (ISPs) containing clonally amplified DNA we 721 
used the Ion OneTouchTM Instrument with the Ion PGMTM Template OT2 400 Kit (ThermoFisher). 722 
Sequencing was performed using the Ion PGMTM Sequencing 400 Kit and Ion 316TM Chip V2 within the Ion 723 
PGMTM System (Thermo Fisher)130.  724 
     Raw sequences were first loaded into the QIIME 1.9.1 pipeline, as described131 using custom analysis 725 
scripts for analysis on the UBELIX Linux cluster of the University of Bern. Only samples with more than 4500 726 
high quality reads were then used for further analysis using R packages. Operational taxonomic units were 727 
picked using UCLUST with a 97% sequence identity threshold, using the default options as implemented in 728 
QIIME and followed by taxonomy assignment using the latest Greengenes database 729 
(greengenes.secondgenome.com). OTUs that were not present in at least 0.01% of our samples or with a 730 
low abundance (<0.001% of the total counts) were filtered out. In combination with the detailed clinical 731 
patient metadata (diagnosis, age, BMI, inflammation status, location of biopsy, disease severity, treatment 732 
etc.) Principal Coordinates Analysis were performed to determine whether samples with certain properties 733 
cluster. Due to the limitations of the resolution on taxonomical classification using 16S gene sequencing 734 
technique, analyses were restricted to genus level.  The OTU abundance biom file and mapping file were 735 
used for statistical analyses and data visualization in the R statistical programming environment package 736 
phyloseq132. Calculation of the α-diversity (Observed OTUs, Simpson and Shannon index), b-diversity (Bray-737 
Curtis genus-level community dissimilarities, weighted and unweighted UniFrac-based PCoA), and 738 
statistical analysis of clustering using Mann-Whitney U tests for alpha diversity and Adonis (PERMANOVA) 739 
for beta diversity to confirm that the strength and statistical significance of groups in the same distance 740 
metrics in the QIIME pipeline and phyloseq in R132,133. Multivariate homogeneity of group dispersion was 741 
to calculate the average distance of the groups and to test if the dispersion of any group was significantly 742 
different from the others. Using k-nearest neighborhood networks created by thresholding the Jaccard 743 
dissimilarity matrix, the differences in microbial community diversities between biopsies collected from 744 
different locations (ileum, colon or rectum) for both cohorts were analyzed. Further analyses were 745 
performed using a Random Forest supervised learning algorithm with additional Boruta feature selection 746 
to identify the most important predictive taxa or community within microbial communities in R. 747 
Hierarchical All-against-All significance testing (HAllA)134 and multivariate analysis by linear models 748 
(MaAsLin) R package135 were used to find associations between clinical metadata (age, BMI, gender, 749 
smoking habits, medication, inflammation status, anatomic location etc.) and microbial community 750 
abundance. The Q-value package was implemented in MaAsLin to correct for multiple testing (Benjamini-751 
Hochberg false discovery rate correction; a false discovery rate [FDR], q-value) of 0.05. Taxa present in at 752 
least 30% of the samples and taxa that had more than 0.0001% of total abundance were set as the cut-off 753 
values for further analysis. After correction for a false discovery rate, q<0.05 was considered significant.  754 
Notable near-significant differences (0.05<p and 0.05<q<0.2) were also highlighted in the figures. Non-755 
significant data were indicated in figures by “n.s”. 756 
    All the relevant codes for running the MaAsLin and HAllA pipeline are available in Dr. Huttenhower’s 757 
group webpage (https://huttenhower.sph.harvard.edu). Plots were generated with ggplot2 using phyloseq 758 
object or Graphpad Prism v7.0a. 759 
    Biopsies (1255 samples in Cohort 1 and 1846 in Cohort 2) from different pre-defined positions along the 760 
length of the colon and the distal small intestine (terminal ileum) from each patient generated 35,678,215 761 
and 40,879,931 high-quality 16S rDNA reads with an average amplicon length of 293bp (Supplementary 762 
Tables 1 and 2). Sequences were clustered into 359,010 and 392,170 taxa respectively based on their 763 
shared sequence similarity at a 97% threshold (3% sequence divergence)136. The average estimated 764 
coverage for OTU characterization was 94.2% and 93.2% 136,137. 765 
 766 
Microbial association network construction within disease status 767 
    Co-occurrence analyses were performed based on the organization of the data generated by phyloseq 768 
object in R. Network analyses were performed using the scripts reported by Williams et al.138. Briefly, we 769 
considered the co-occurrence to be positive rank correlations identified using Spearman’s correlation 770 
between identified taxa within each disease condition. Positive correlation (weak correlation: r-value > 771 
0.25 and strong correlation: r-value > 0.5) helped us to identified even relatively less strong and highly 772 
correlated significant positive correlations between co-occurring taxa in each identified ecosystem, 773 
respectively. The OTUs that had more than 0.0001% total of relative abundance and taxa present in at least 774 
30% of the samples were retained for further statistical analysis and illustration of the significant co-775 
occurrence network between microbial taxa. We thus obtained a data frame that listed disease status, the 776 
originating environment of the samples, assigned taxa, Spearman’s correlation coefficient, p value 777 
calculated using PERMANOVA, and the abundances of each taxa. We calculated the modules detected 778 
using Vertex and edge betweenness centrality functions in igraph package and generated betweenness 779 
score for each microbial taxon. The ‘betweenness centrality scores’ for each vertex is the number of these 780 
shortest paths going through a node and ‘eigenvector centrality‘ is a measure of node connectivity to 781 
important neighbors in a given network. Spearman’s correlation coefficients calculated between the 782 
different co-occurring taxa within each environment were used for generating network plots. Igraph 783 
objects were transferred into Cytoscape using RJSONIO and httr packages in R. The community structure 784 
analysis of biological co-occurrence network carried out using GLay implemented into Cytoscape as a fast-785 
greedy algorithm139. Network plots were generated using a customized organic layout of Cytoscape v.3.5.1.  786 
 787 
Reaction-level analysis 788 
     OTUs were mapped to metabolic reactions via a previously published collection of genome-scale 789 
metabolic models (GSMMs)140. We included OTUs that could be mapped to a taxonomic rank of family or 790 
lower and to at least one GSMM. The normalized abundance of a reaction 𝑖 in a patient sample, 𝑎#(𝑖) was 791 
calculated as: 792 
𝑎#(𝑖) ='𝑎()*(𝑗)𝐸(𝑖, 𝑗)
.
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 794 
where 𝑎()*(𝑗) is the abundance of OTU 𝑗 in the patient sample, 𝑁 is the number of detected OTUs, and 795 
𝐸(𝑖, 𝑗) is the expected probability (frequency of occurrences) of reaction 𝑖 in the GSMMs associated with 796 
OTU 𝑗. To analyze metabolic reaction differences between patient groups, a two-sample t-test was used to 797 
compare the mean abundances of each reaction and each binary patient classification of interest (e.g., UC 798 
vs. CD) between the two groups. The Benjamini-Hochberg procedure141 was applied to correct for multiple 799 
testing and adj-p-value ≤ 0.05 between groups was considered significant. The metabolic subsystem 800 
classification of reactions was obtained from the GSMMs and for each t-test comparing groups of patients 801 
and each subsystem, Fisher’s exact test was performed to determine if the subsystem was overrepresented 802 
among the significantly different reactions; subsystems with p-value ≤ 0.05 were considered enriched. All 803 
analyses were performed in MATLAB (R2018a).  804 
 805 
Fecal calprotectin 806 
    Calprotectin is a member of the S100 family of calcium binding proteins found in the cytosol of 807 
neutrophils and thus, abundant in all body fluids in proportion to the degree of inflammation present. Fecal 808 
calprotectin was measured by a quantitative enzyme-linked immunosorbent assay after using Calprotectin 809 
– Stool Extraction with CALEX. The assays were carried out according to the instructions (The BÜHLMANN 810 
fecal Calprotectin Assays, BÜHLMANN Laboratories AG, Schönenbuch, Switzerland). All fecal samples were 811 
processed within 72h after collection. The assay plates were read at an OD450 nm as instructed in 812 
manufacture’s documentation. The calprotectin cut-off level representing a positive value was ≥ 50μg 813 
calprotectin/gr stool. 814 
 815 
Search Strategy and Data Extraction 816 
    We systematically searched the publications in PubMed (including MEDLINE), and Google Scholar. The 817 
electronic search algorithm consisted of terms relating to key concepts of “inflammatory bowel disease”, 818 
“IBD”, “microbiome”, “gut microbiota”, “metagenomic”, “16S rDNA”, “human”, “mice”, “cats”, “dogs”, 819 
“animal models”, “naturally induced colitis” and “chemically induced colitis”. Reference lists of included 820 
articles, related reviews, and other relevant sources were manually searched. After initial screening of titles 821 
and abstracts, full text assessments were performed for eligibility of the data to include into the figure. 822 
Characteristics of each eligible study were extracted: disease information, species, race (ethnicity), gender, 823 
age (median year), number of samples used for sequencing, type of samples, method of characterization 824 
of the microbiota, model of inflammation induction. Results of included studies were then organized, and 825 
corresponding heat-maps generated using Euclidean clustering of sample annotations (vertical) including 826 
race/ethnicity, gender, median age, patient number, sample type, model of inflammation induction, 827 
sequencing method and microbial taxa (horizontal) at different taxonomic ranks. 828 
 829 
Reporting Summary  830 
Further information on research design is available in the Nature Research Reporting Summary linked to 831 
this article. 832 
 833 
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Yilmaz et al. Extended Data Fig.10
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